ABOUT US
WE ARE ENGINEERING THE TARGETED PROTEIN DEGRADATION TOOLBELT TO EMPOWER A NEW PARADIGM OF DRUG DISCOVERY SCIENTISTS
Differentiated Therapeutics is pioneering the discovery, design, and optimization of novel protein degraders, that are designed to be disease-modifying and target the underlying cause of disease. To date, we are executing TPD strategies for mendelian diseases and targeted oncology indications.
The protein degradation opportunity is immense and reaches across a broad range of disease areas in which new and enhanced treatments are needed. Biological insight, medicinal chemistry experience, and drug discovery expertise as well as cutting-edge computational tools such as artificial intelligence and physics-based simulation will be essential to improve the probability of success, time, and cost involved to deliver the best therapies to patients in need.
WE ARE DIFFERENTIATED THERAPEUTICS
Differentiated Therapeutics (dx/tx) is a protein degradation company focused on discovering and developing transformative medicines to treat patients with life-altering diseases.
We are pursuing this expansive field of discovery, speedily scaling up our research while maintaining intentionality for what their future holds - it's an exciting time! Our team integrates extensive biology knowledge and a drug hunter’s intuition leveraging our proprietary Auto/dx platform to deliver a robust pipeline spanning multiple molecular targets in various therapeutic areas; these combine together into something truly remarkable: end-to-end discovery capabilities and world-class collaborators in the field of protein degradation to propel us ahead in our mission
LEADERSHIP
STEPHANE BILLOTTE
Project Management
ANDREW SONDERFAN
Toxicology
ADVISORS
ZAK KOHANE, MD, PhD
Co-founder, Chair of the Department of Biomedical Informatics, Harvard Medical School
PETER SICINSKI, MD, PhD
Professor of Genetics, Harvard Medical School
GOTTFRIED KONECNY, MD
Professor, David Geffen School of Medicine at UCLA
